Table 4.
Azacitidine Dosing
| Result | |
|---|---|
| Started Azacitidine | 41 |
| Reasons for ending protocol treatment prior to starting Azacitidine | |
| Death | 8 (36%) |
| Progression | 4 (18%) |
| AE | 5 (23%) |
| Refusal | 2 (9%) |
| Other1 | 3 (14%) |
| Time from transplant to start of Azacitidine (days), median (range) | 61 (43–91) |
| Number of Azacitidine received | |
| 1 | 4 (9.8%) |
| 2 | 4 (9.8%) |
| 3 | 5 (12.2%) |
| 4 | 5 (12.2%) |
| 5 | 5 (12.2%) |
| 6 | 18 (43.9%)2 |
| Completed Azacitidine | 17 (41%) |
| Reasons for ending protocol treatment prior to completing Azacitidine | |
| Death | 4 (17%) |
| Progression | 6 (25%) |
| AE | 5 (21%) |
| Refusal | 8 (33%) |
| Other3 | 1 (4%) |
1:
Patient scheduled to receive bone marrow stem cells not allowed per protocol; could not start AZA due to low ANC on day 90; Pt started on Valcyte for CMV which caused low counts, never met criteria to start AZA
2:
1 patient stated cycle 6, but only received doses 1 and 2; doses 3–5 were missed due to sepsis. Therefore they did not complete treatment per protocol
3:
Treatment delayed greater than 4 weeks due to AE not related to protocol